Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective.

MLA

King, Catherine, et al. “Rapid Transition to Home Omalizumab Treatment for Chronic Spontaneous Urticaria during the COVID-19 Pandemic: A Patient Perspective.” The World Allergy Organization Journal, vol. 14, no. 10, Oct. 2021, p. 100587. EBSCOhost, https://doi.org/10.1016/j.waojou.2021.100587.

APA

King, C., Cox, F., Sloan, A., McCrea, P., Edgar, J. D., & Conlon, N. (2021). Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective. The World Allergy Organization Journal, 14(10), 100587. https://doi.org/10.1016/j.waojou.2021.100587

Chicago

King, Catherine, Fionnuala Cox, Anne Sloan, Patricia McCrea, J David Edgar, and Niall Conlon. 2021. “Rapid Transition to Home Omalizumab Treatment for Chronic Spontaneous Urticaria during the COVID-19 Pandemic: A Patient Perspective.” The World Allergy Organization Journal 14 (10): 100587. doi:10.1016/j.waojou.2021.100587.